GUCY1A2

GUCY1A2 encodes the α2 subunit of soluble guanylate cyclase (sGC), which heterodimerizes with the β1 subunit to form a heme-containing, NO-sensitive cyclase (α2β1) with kinetic properties and pharmacological responses indistinguishable from the canonical α1β1 isoform (PMID:9742221, PMID:1683630). A C-terminal PDZ-binding motif unique to α2 recruits the α2β1 heterodimer to synaptic membranes via PSD-95 and also mediates interaction with the scaffold protein Scribble, establishing a compartmentalized NO–cGMP signaling module distinct from cytosolic α1β1 (PMID:11572861, PMID:24550280). Activity of the α2β1 complex is regulated post-transcriptionally by a dominant-negative splice variant (α2i) that competes for β1 binding without catalytic output, and post-translationally by CHIP E3 ligase-mediated, HSP90/HSP70-dependent ubiquitination and proteasomal degradation (PMID:7673142, PMID:17873020). A de novo gain-of-function missense variant (p.E486D) that increases NO affinity causes a syndrome of autonomous ovarian puberty with intellectual disability, directly linking α2β1 hyperactivity to human disease (PMID:38578777).

1. 1991 High

   Cloning of GUCY1A2 established that an alternative α subunit can substitute for α1 to form a catalytically active, NO-responsive sGC heterodimer with β1, resolving whether sGC subunit composition is flexible.

   Evidence cDNA cloning and coexpression activity assays in COS cells

   PMID:1683630

   Open questions at the time

   • No information on native protein expression or tissue-specific function
   • Relative contribution of α2β1 versus α1β1 in vivo unknown
2. 1995 High

   Discovery of a catalytically dead splice variant (α2i) that retains β1 heterodimerization and acts as a dominant negative revealed a post-transcriptional mechanism for tuning sGC output.

   Evidence Molecular cloning, coexpression in Sf9 and COS-7 cells, copurification, and competitive coexpression activity assays

   PMID:7673142

   Open questions at the time

   • In vivo expression levels and tissue distribution of α2i not determined
   • Physiological contexts where dominant-negative regulation is operative remain undefined
3. 1998 High

   Purification of native α2β1 from human placenta proved this isoform exists as a functional heme-containing enzyme in vivo, with spectral and kinetic properties identical to α1β1.

   Evidence Co-precipitation from human placenta, Sf9-expressed protein purification, UV-vis spectroscopy, kinetic assays with NO/CO/YC-1/ODQ

   PMID:9742221

   Open questions at the time

   • Whether α2β1 has any unique regulatory properties in native tissue not addressed
   • Relative abundance of α2β1 versus α1β1 in placenta not quantified
4. 2001 High

   Identification of the α2–PSD-95 interaction via the α2 C-terminal PDZ-binding motif explained how α2β1, but not α1β1, is recruited to synaptic membrane fractions, establishing isoform-specific subcellular compartmentalization near neuronal NOS.

   Evidence Coprecipitation from rat brain, recombinant PDZ domain binding assays, synaptosome subcellular fractionation

   PMID:11572861

   Open questions at the time

   • Functional consequence of synaptic targeting for cGMP signaling not directly tested
   • Whether other PDZ scaffold partners contribute to α2β1 localization in neurons unknown
5. 2007 High

   Demonstration that CHIP ubiquitinates sGC (including the α2-containing form) in an HSP90/HSP70-dependent manner and targets it for proteasomal degradation revealed a chaperone-coupled quality-control pathway governing sGC protein stability.

   Evidence In vitro ubiquitination with purified proteins, domain-mutant CHIP constructs, MG-132 rescue, geldanamycin treatment in COS-7 and rat aortic smooth muscle cells, aortic ring relaxation assay

   PMID:17873020

   Open questions at the time

   • Relative susceptibility of α2β1 versus α1β1 to CHIP-mediated degradation not compared
   • In vivo relevance of this pathway to α2β1 turnover in brain or placenta not examined
6. 2014 High

   Structural and biophysical studies showed that heterodimerization of catalytic domains is necessary but insufficient for full activity, with an interfacial flap and hydrogen-bond network required for productive subunit alignment — explaining why regulatory-domain interactions tune catalytic output beyond simple subunit assembly.

   Evidence X-ray crystallography of isolated catalytic domains, native mass spectrometry, in vitro activity measurements

   PMID:24669844

   Open questions at the time

   • Full-length α2β1 structure not resolved
   • How NO-induced conformational changes propagate through the interfacial flap unknown
7. 2014 Medium

   Identification of Scribble as a second PDZ-scaffold partner for the α2 C-terminus expanded the repertoire of compartmentalization mechanisms and suggested polarity-related signaling roles for α2β1.

   Evidence Proteomic peptide-phage display, coimmunoprecipitation and colocalization of full-length proteins, recombinant PDZ affinity measurements

   PMID:24550280

   Open questions at the time

   • Functional consequence of the α2–Scribble interaction on cGMP signaling not tested
   • Tissue context where this interaction is physiologically relevant not defined
   • Single study without independent replication
8. 2024 High

   A de novo gain-of-function GUCY1A2 variant (p.E486D) causing increased NO affinity and elevated cGMP was linked to precocious peripheral puberty and intellectual disability, providing the first direct human disease association and demonstrating that even modest shifts in NO sensitivity have major physiological consequences.

   Evidence Exome sequencing, concentration-response assays in HEK293T, UV-vis spectroscopy of purified enzyme, confocal microscopy

   PMID:38578777

   Open questions at the time

   • Mechanism by which elevated cGMP causes both ovarian and neurological phenotypes not delineated
   • Whether loss-of-function variants produce a reciprocal human phenotype unknown

• A full-length structure of the α2β1 heterodimer, the in vivo signaling consequences of synaptic targeting via PSD-95/Scribble, and the tissue-specific physiological roles distinguishing α2β1 from α1β1 remain unresolved.
• No full-length α2β1 cryo-EM or crystal structure
• Genetic models specifically disrupting α2β1 in brain are lacking
• Relative in vivo contribution of α2β1 versus α1β1 to NO–cGMP signaling in each tissue not quantified